The in vitro anti-viral potential of Setarud (IMOD), a commercial herbal medicine with protective activity against acquired immune deficiency syndrome in clinical trials

Indian Journal of Pharmacology

Volumn 44, Issue 4, 2012, Pages 448-453

  Zabihollahi, Rezvan ^a   Namazi, Rahele ^b   Aghasadeghi, Mohammad Reze ^a   Esfahani, Azar Farhang ^c   Seyed Mehdi Sadat, ^a   Modarressi, Mohammad Hossein ^d  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b UNIVERSITY OF ISFAHAN   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti viral activity; human immunodeficiency virus; setarud (IMOD)

Indexed keywords

ANTIGEN P24; ANTIVIRUS AGENT; GREEN FLUORESCENT PROTEIN; IMOD; PLANT MEDICINAL PRODUCT; SETARUD; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HERBAL MEDICINE; HERPES SIMPLEX; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IN VITRO STUDY; LEUKEMIA VIRUS; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; VIRUS ENTRY; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTI-VIRAL ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; SETARUD (IMOD™);

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CLINICAL TRIALS AS TOPIC; HEK293 CELLS; HIV-1; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; VERO CELLS;

EID: 84865719145     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.99301     Document Type: Article

References (32)

1. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-71.
2. Arora DR, Gautam V, Gill PS, Mishra N. Recent advances in antiretroviral therapy in HIV infection. J Indian Med Assoc 2010;108:29-34.
3. Wilkin TJ, Shalev N, Tieu HV, Hammer SM. Advances in antiretroviral therapy. Top HIV Med 2010;18:66-92.
4. Cohen J. HIV/AIDS. Tangled patent dispute over 'free' drug-resistance database. Science 2009;323:1156-7.
5. Obiako OR, Murktar HM, Ogoina D. Antiretroviral drug resistance- implications for HIV/AIDS reduction in sub-saharan Africa and other developing countries. Niger J Med 2010;19:302-10.
6. Novitsky YA, Madani H, Gharibdoust F, Farhadi M, Farzamfar B, Mohraz M, In-ventors; Parsroos corporation. Use of a combination of ethanolic rosa sp., urtica dioica and tanacetum vulgare extracts, further comprising selenium and urea and having been exposed to a pulsed electromagnetic field, for the preparation of a medicament for immunostimulation and/or treatment of hiv infections. EU patent WO/2007/087825. 2007 Aug 9. Other Published Materials.
7. Mohraz M, Khairandish P, Kazerooni PA, Davarpanah MA, Shahhosseiny MH, Mahdavian B, et al. A clinical trial on the efficacy of IMOD in AIDS patients. DARU 2009;17:277-83.
8. Khairandish P, Mohraz M, Farzamfar B, Abdollahi M, Shahhosseiny MH, Madani H, et al. Preclinical and phase 1 clinical safety of setarud (IMOD™), a novel immunomodulator. DARU 2009;17:148-57.
9. Khorramkhorshid HR, Novitsky YA, Abdollahi M, Shahhosseiny MHS, Madani H, Rahimi R, et al. Studies on potential mutagenic and genotoxic activity of setarud. DARU 2008;16:223-8.
10. Baghaei A, Esmaily H, Abdolghaffari AH, Baeeri M, Gharibdoost F, Abdollahi M. Efficacy of setarud (IMOD®), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Indian Journal of Biochemistry and Biophysics 2010;47:219-26.
11. Mahmoodpoor A, Eslami K, Mojtahedzadeh M, Najafi A, Ahmadi A, Dehnadi-Moghadam A, et al. Examination of setarud (IMOD™) in the management of patients with severe sepsis. DARU 2010;18:23-8.
12. Azonov JA, Khorramkhorshid HR, Novitsky YA, Farhadi M, Ghorbanoghli Z, Shahhosseiny MH. Protective effects of setarud (IMOD™) on development of diet-induced hypercholesterolemia in rabbits. DARU 2008;16:218-22.
13. Khorramkhorshid HR, Azonov JN, Novitsky YA, Farzamfar B, Shahhosseiny MH. Hepatoprotective effects of setarud against carbon tetrachloride-induced liver injury in rats. Indian J Gastroenterol 2008;27:110-2.
14. Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006;80:2463-71.
15. Zabihollahi R, Sadat SM, Vahabpour R, Aghasadeghi MR, Memarnejadian A, Ghazanfari T, et al. Development of single-cycle replicable human immunodeficiency virus 1 mutants. Acta Virol 2011;55:15-22.
16. Rezaei A, Zabihollahi R, Salehi M, Moghim S, Tamizifar H, Yazdanpanahi N, et al. Designing a non-virulent HIV-1 strain: Potential implications for vaccine and experimental research. J Res Med Sci 2007;12:227-34.
17. Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, Pommier Y, et al. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions. J Virol 2004;78:3210-22.
18. Cavrois M, Neidleman J, Yonemoto W, Fenard D, Greene WC. HIV-1 virion fusion assay: Uncoating not required and no effect of Nef on fusion. Virology 2004;328:36-44.
19. Lin PF, Blair W, Wang T, Spicer T, Guo Q, Zhou N, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003;100:11013-8.
20. Patwardhan B, Gautam M. Botanical immunodrugs: Scope and opportunities. Drug Discov Today 2005;10:495-502.
21. Bedoya LM, Sanchez-Palomino S, Abad MJ, Bermejo P, Alcami J. Anti-HIV activity of medicinal plant extracts. J Ethnopharmacol 2001;77:113-6.
22. Alvarez AL, Habtemariam S, Juan-Badaturuge M, Jackson C, Parra F. In vitro anti HSV-1 and HSV-2 activity of tanacetum vulgare extracts and isolated compounds: An approach to their mechanisms of action. Phytother Res 2011;25:296-301.
23. Uncini Manganelli RE, Zaccaro L, Tomei PE. Antiviral activity in vitro of Urtica dioica L., Parietaria diffusa M. et K. and Sambucus nigra L. J Ethnopharmacol 2005;98:323-7.
24. Kirkeskov B, Christensen R, Bugel S, Bliddal H, Danneskiold-Samsoe B, Christensen LP, et al. The effects of rose hip (Rosa canina) on plasma antioxidative activity and C-reactive protein in patients with rheumatoid arthritis and normal controls: A prospective cohort study. Phytomedicine 2011;18:953-8.
25. Serteser A, Kargioglu M, Gok V, Bagci Y, Ozcan MM, Arslan D. Determination of antioxidant effects of some plant species wild growing in Turkey. Int J Food Sci Nutr 2008;59:643-51.
26. Gurbuz I, Ustun O, Yesilada E, Sezik E, Kutsal O. Anti-ulcerogenic activity of some plants used as folk remedy in Turkey. J Ethnopharmacol 2003;88:93-7.
27. Xie G, Schepetkin IA, Quinn MT. Immunomodulatory activity of acidic polysaccharides isolated from tanacetum vulgare L. Int Immunopharmacol 2007;7:1639-50.
28. Kandis H, Karapolat S, Yildirim U, Saritas A, Gezer S, Memisogullari R. Effects of urtica dioica on hepatic ischemia-reperfusion injury in rats. Clinics (Sao Paulo) 2010;65:1357-61.
29. Tarhan O, Alacacioglu A, Somali I, Sipahi H, Zencir M, Oztop I, et al. Complementary-alternative medicine among cancer patients in the western region of Turkey. J BUON 2009;14:265-9.
30. Namazi N, Esfanjani AT, Heshmati J, Bahrami A. The effect of hydro alcoholic nettle (Urtica dioica) extracts on insulin sensitivity and some inflammatory indicators in patients with type 2 diabetes: A randomized double-blind control trial. Pak J Biol Sci 2011;14:775-9.
31. Harput US, Saracoglu I, Ogihara Y. Stimulation of lymphocyte proliferation and inhibition of nitric oxide production by aqueous Urtica dioica extract. Phytother Res 2005;19:346-8.
32. Madani N, Schon A, Princiotto AM, Lalonde JM, Courter JR, Soeta T, et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008;16:1689-701.